Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer

Annals of Internal Medicine

Volumn 152, Issue 10, 2010, Pages 621-629

  Ito, Kouta ^a,b   Elkin, Elena B ^a,b   Girotra, Monica ^a,b   Morris, Michael J ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BONE DENSITY CONSERVATION AGENT; GONADORELIN;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE DENSITY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RISK; COST EFFECTIVENESS ANALYSIS; DRUG COST; HIDDEN MARKOV MODEL; HIP FRACTURE; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; SENSITIVITY ANALYSIS; AGED; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; DISEASE COURSE; DRUG POTENTIATION; HUMAN; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; ORCHIECTOMY; PATHOPHYSIOLOGY; PROBABILITY; PROSTATE TUMOR; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR;

AGED; AGED, 80 AND OVER; ALENDRONATE; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COMBINED MODALITY THERAPY; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; GONADOTROPIN-RELEASING HORMONE; HIP FRACTURES; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; ORCHIECTOMY; OSTEOPOROSIS; PROSTATIC NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS;

EID: 77952967783     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-152-10-201005180-00002     Document Type: Article

References (75)

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. v.l.2010. Fort Washington, PA: National Comprehensive Cancer Network; 2010. Accessed at www.nccn.org/professionals /physician-gls/PDF/prostate.pdf [registration required] on 1 February 2010.
2. American Urological Association. Guideline for the management of clinically localized prostate cancer: 2007 Update. Baltimore: American Urological Assoc; 2007. Accessed at www.auanet.org/content/guidelines-and- quality-care/clinical -guidelines/main-reports/proscan07/content.pdf on 1 February 2010.
3. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008;148:435-48. [PMID: 18252677]
4. Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol. 1999;161:1219-22. [PMID: 10081873] (Pubitemid 29426121)
5. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 2000;163:181-6. [PMID: 10604342]
6. Berruti A, Dogliotti L, Terrone C, Cerutti S, Isaia G, Tarabuzzi R, et al; Gruppo Onco Urologico Piemontese (G.O.U.P.), Rete Oncologica Piemontese. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol. 2002; 167:2361-7; discussion 2367. [PMID: 11992038]
7. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154-64. [PMID: 15647578]
8. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23: 7897-903. [PMID: 16258089]
9. Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol. 2006;175:136-9; discussion 139. [PMID: 16406890]
10. Tanvetyanon T. Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy. Cancer. 2005;103:237-41. [PMID: 15597384] (Pubitemid 40129281)
11. Alibhai SM, Rahman S, Warde PR, Jewett MA, Jaffer T, Cheung AM. Prevention and management of osteoporosis in men receiving androgen deprivation therapy: a survey of urologists and radiation oncologists. Urology. 2006;68: 126-31. [PMID: 16844454]
12. Wilcox A, Carnes ML, Moon TD, Tobias R, Baade H, Stamos E, et al. Androgen deprivation in veterans with prostate cancer: implications for skeletal health. Ann Pharmacother. 2006;40:2107-14. [PMID: 17132807]
13. Yee EF, White RE, Murata GH, Handanos C, Hoffman RM. Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy. J Gen Intern Med. 2007;22:1305-10. [PMID: 17634780]
14. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer. 2004;100:892-9. [PMID: 14983482]
15. Eastham JA. Bone health in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2007;177:17-24. [PMID: 17161994]
16. Greenspan SL. Approach to the prostate cancer patient with bone disease. J Clin Endocrinol Metab. 2008;93:2-7. [PMID: 18178905]
17. Saad F, Adachi JD, Brown JP, Canning LA, Gelmon KA, Josse RG, et al. Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol. 2008;26:5465-76. [PMID: 18955443]
18. Allain TJ. Prostate cancer, osteoporosis and fracture risk. Gerontology. 2006; 52:107-10. [PMID: 16508318]
19. Polascik TJ. Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates. Prostate Cancer Prostatic Dis. 2008;11:13-9. [PMID: 17923854]
20. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343: 604-10. [PMID: 10979796]
21. Ringe JD, Faber H, Farahmand P, Dorst A. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int. 2006;26:427-31. [PMID: 16001181] (Pubitemid 43318323)
22. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med. 2007;146:416-24. [PMID: 17371886]
23. Greenspan SL, Nelson JB, Trump DL, Wagner JM, Miller ME, Perera S, et al. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J Clin Oncol. 2008;26:4426-34. [PMID: 18802155]
24. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345:948-55. [PMID: 11575286]
25. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169:2008-12. [PMID: 12771706]
26. Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89:3841-6. [PMID: 15292315]
27. Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol. 2006;176:972-8; discussion 978. [PMID: 16890673]
28. Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol. 2007;25:1038-42. [PMID: 17369566]
29. Israeli RS, Rosenberg SJ, Saltzstein DR, Gottesman JE, Goldstein HR, Hull GW, et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer. 2007;5: 271-7. [PMID: 17553207]
30. Smith MR, Malkowicz SB, Chu F, Forrest J, Price D, Sieber P, et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol. 2008;179:152-5. [PMID: 18001802]
31. Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, et al; Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745-55. [PMID: 19671656]
32. Gold MR, Seigel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford Univ Pr; 1996.
33. Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008;26:2497-504. [PMID: 18413638]
34. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA. 2008;300:173-81. [PMID: 18612114]
35. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int. 1998;8:468-89. [PMID: 9850356]
36. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al; FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296:2927-38. [PMID: 17190893]
37. Scher HI, Heller G. Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology. 2000;55:323-7. [PMID: 10699601] (Pubitemid 30110575)
38. De Laet CE, van Hout BA, Burger H, Hofman A, Pols HA. Bone density and risk of hip fracture in men and women: cross sectional analysis. BMJ. 1997; 315:221-5. [PMID: 9253270] (Pubitemid 27326329)
39. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005; 20:1185-94. [PMID: 15940371]
40. Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005;23:2918-25. [PMID: 15860850]
41. Hummel S, Paisley S, Morgan A, Currie E, Brewer N. Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review. Health Technol Assess. 2003;7:iii, ix-x, 1-157. [PMID: 14609482]
42. Hannan MT, Felson DT, Dawson-Hughes B, Tucker KL, Cupples LA, Wilson PW, et al. Risk factors for longitudinal bone loss in elderly men and women: the Framingham Osteoporosis Study. J Bone Miner Res. 2000;15:710-20. [PMID: 10780863] (Pubitemid 30174025)
43. Kiratli BJ, Srinivas S, Perkash I, Terris MK. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology. 2001;57:127-32. [PMID: 11164157]
44. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22:465-75. [PMID: 17144789]
45. Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004;35: 375-82. [PMID: 15268886]
46. Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007;82:1493-501. [PMID: 18053457]
47. Cadarette SM, Katz JN, Brookhart MA, Stürmer T, Stedman MR, Levin R, et al. Comparative gastrointestinal safety of weekly oral bisphosphonates. Osteoporos Int. 2009;20:1735-47. [PMID: 19266138]
48. Arias E. United States life tables, 2004. National vital statistics reports. Volume 56, number 9. Hyattsville, MD: National Center for Health Statistics; 2007. Accessed at www.cdc.gov/nchs/data/nvsr/nvsr56/nvsr56-09.pdf on 1 February 2010.
49. Dawson-Hughes B, Tosteson AN, Melton LJ 3rd, Baim S, Favus MJ, Khosla S, et al; National Osteoporosis Foundation Guide Committee. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int. 2008;19:449-58. [PMID: 18292975]
50. Kanis JA, Johansson H, Oden A, Jonsson B, Johnell O, De Laet C. How many deaths from hip fracture might be prevented [Abstract]. J Bone Miner Res. 2002;17(Suppl 1):S146.
51. Kattan MW, Cowen ME, Miles BJ. A decision analysis for treatment of clinically localized prostate cancer. J Gen Intern Med. 1997;12:299-305. [PMID: 9159699]
52. Kanis JA, Johnell O, Oden A, Borgstrom F, Zethraeus N, De Laet C, et al. The risk and burden of vertebral fractures in Sweden. Osteoporos Int. 2004;15: 20-6. [PMID: 14593450]
53. Schousboe JT, Taylor BC, Fink HA, Kane RL, Cummings SR, Orwoll ES, et al. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA. 2007;298:629-37. [PMID: 17684185]
54. Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, et al; National Osteoporosis Foundation Guide Committee. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int. 2008;19:437-47. [PMID: 18292976]
55. Winstead NS, Wilcox CM. Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2007;26:1371-7. [PMID: 17848180]
56. Center for Medicare and Medicaid Services. Physician fee schedule search: 2007. Accessed at www.cms.hhs.gov/PFSlookup/02-PFSSearch.asp on 1 February 2010.
57. New York State Department of Health. Prescription drug prices in New York State. Accessed at http://rx.nyhealth.gov/pdpw/ on 1 February 2010.
58. Gabriel SE, Tosteson AN, Leibson CL, Crowson CS, Pond GR, Hammond CS, et al. Direct medical costs attributable to osteoporotic fractures. Osteoporos Int. 2002;13:323-30. [PMID: 12035765]
59. Tosteson AN, Rosenthal DI, Melton LJ 3rd, Weinstein MC. Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med. 1990;113:594-603. [PMID: 2119161]
60. U.S. Office of Technology Assessment. Effectiveness and Costs of Osteoporosis Screening and Hormone Replacement Therapy. Volume 2: Evidence on Benefits, Risks, and Costs. Washington, DC: Congress Office of Technology Assessment, Congress of the United States; 1995.
61. Ross JR, Saunders Y, Edmonds PM, Patel S, Broadley KE, Johnston SR. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ. 2003;327:469. [PMID: 12946966]
62. U.S. Department of Labor. U.S. Consumer Price Index for Medical Care for All Urban Consumers. Accessed at www.bls.gov/cpi/ on 1 February 2010.
63. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med. 2003;163: 1637-41. [PMID: 12885677]
64. Qaseem A, Snow V, Shekelle P, Hopkins R Jr, Forciea MA, Owens DK; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;148:680-4. [PMID: 18458281]
65. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Accessed at www.nof.org/professionals/NOF-Clinicians- Guide.pdf on 1 February 2010.
66. WHO fracture risk assessment tool. Accessed at www.shef.ac.uk/FRAX/ on 1 February 2010.
67. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett- Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-82. [PMID: 9875874]
68. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al; Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344:333-40. [PMID: 11172164]
69. Simonelli C, Killeen K, Mehle S, Swanson L. Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons. Mayo Clin Proc. 2002;77:334-8. [PMID: 11936928]
70. DesHarnais Castel L, Bajwa K, Markle JP, Timbie JW, Zacker C, Schulman KA. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support Care Cancer. 2001;9:545-51. [PMID: 11680835]
71. Qaseem A, Snow V, Shekelle P, Hopkins R Jr, Forciea MA, Owens DK; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;149:404-15. [PMID: 18794560]
72. Miksad RA, Come S, Weinstein M. The quality-of-life impact of osteonecrosis of the jaw: implications for bisphosphonate use in metastatic breast cancer. J Clin Oncol. 2007;25(Suppl 18):6620.
73. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753-61. [PMID: 16702591]
74. Edwards BJ, Gounder M, McKoy JM, Boyd I, Farrugia M, Migliorati C, et al. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol. 2008;9:1166-72. [PMID: 19038763]
75. The Endocrine Society. Position statement: Medicare coverage of DXA bone density testing in men. June 2009. Accessed at www.endo-society.org/advocacy /policy/upload/Medicare-Coverage-of-DXA-Bone-Density-Testing-in-Men-Position- Statement-2.pdf on 1 February 2010.